CD274 and neoplasm: Although some reported that TMB was a potential predictive biomarker for response to ICIs in BTC patients [25] and pretreatment PD-L1 expression on the tumor was significantly associated with prolonged PFS with nivolumab [26], the antitumor activity of pembrolizumab was found to be independent of PD-L1 expression and TMB in this study.